New study checks safety of popular wrinkle filler

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Individuals treated or planned to be treated with saypha® filler for moderate to severe nasolabial folds as per IFU. 2. Individuals 18 years of age or older. 3. Individuals who have provided consent for use of their data, either prospectively before, at their first visit, or retrospectively at any point during or after the follow up period. 4. Individuals who are willing to have at least two visits within the surveys' 6 to 11-months period or have already completed the follow-up visits and data are available for at least two visits within the survey's 6 to 11-month period, corresponding to Visit 3 and Visit 4. 5. For retrospective included Individuals who have data available on a 5 grade, validated photo numeric NLF scale and the modified GAIS at baseline and for at least two visits within the survey's 6 to 11-month period, corresponding to Visit 3 and Visit 4, or individuals who are willing to attend any follow-up visit with data collected independently for the left and right nasolabial fold (requiring two assessments each per visit). Exclusion Criteria: 1. Individuals involved in other clinical studies that may interfere with the assessment of this device's performance or safety. 2. Individuals with facial plastic surgery, tissue augmentation with silicone, fat or another non-absorbable substance (permanent fillers) in the area of device application. 3. Individuals that have an implantation of absorbable and non-absorbable facial dermal fillers in the treatment area in the preceding twelve months. 4. Individuals where the skin of the nasolabial region is affected by aesthetic treatments (e.g. laser therapy, absorbable and non-absorbable sutures (threads), microneedling and/or botulinum toxin within the last twelve months, dermabrasion and mesotherapy within the last six months, chemical peeling within the last three months) or planning to undergo such procedures during the survey period. 5. Individuals who had facial lipolysis, including submental fat treatments, within last month prior to enrollment and during the survey period. 6. Individuals currently undergoing a medically supervised or self-initiated diet program aimed at significant weight loss or metabolic change at the time of treatment and/or during the follow-up period. 7. Pregnant or breastfeeding women, as treatment during pregnancy or lactation is contraindicated according to the product's Instructions for Use (IFU).